Leading expert in interventional cardiology and transcatheter aortic valve replacement, Dr. Jeffrey Popma, MD, explains the evolution of TAVR. He compares this minimally invasive procedure to traditional open-heart surgery. Dr. Popma details the benefits for patients, including faster recovery and reduced risk. He discusses the expanding applications of transcatheter technology for various heart valve diseases. His insights are based on decades of experience and leadership in major clinical trials.
More from Diagnostic Detectives Network
Transcatheter Aortic Valve Replacement vs. Open Heart Surgery: A Cardiologist's Guide
Jump To Section
- TAVR vs. Open Heart Surgery
- Benefits of Minimally Invasive TAVR
- Expanding Transcatheter Valve Therapies
- Clinical Trials and Medical Innovation
- Expert Career and Research Highlights
- Full Transcript
TAVR vs. Open Heart Surgery
Dr. Jeffrey Popma, MD, provides a clear comparison between transcatheter aortic valve replacement and traditional surgical aortic valve replacement. The fundamental difference lies in the procedural approach. Open-heart surgery requires a large chest incision, stopping the heart, and using a heart-lung machine. In contrast, TAVR is a minimally invasive procedure performed through a small incision, often in the groin.
The TAVR procedure involves threading a catheter to the diseased aortic valve. A collapsible replacement valve is then deployed within the old valve. This approach avoids the need for sternotomy and cardiopulmonary bypass. Dr. Popma's extensive research has been pivotal in establishing TAVR as a standard of care for many patients.
Benefits of Minimally Invasive TAVR
The benefits of TAVR are significant for patient recovery and outcomes. Patients typically experience a much shorter hospital stay after a TAVR procedure. Recovery time is dramatically reduced compared to the lengthy convalescence from open-heart surgery.
This minimally invasive technique also lowers the risk of certain major complications. There is less blood loss, a lower risk of stroke in some studies, and a reduced chance of infection. As Dr. Jeffrey Popma, MD, explains, these advantages make TAVR a preferred option for high-risk and inoperable patients, and increasingly for those at lower surgical risk.
Expanding Transcatheter Valve Therapies
Dr. Popma's expertise extends beyond the aortic valve to other structural heart diseases. Transcatheter technologies are now being developed for mitral and tricuspid valve repair and replacement. These innovations offer hope for patients with complex valve disease who are not candidates for surgery.
The principles of minimally invasive intervention are revolutionizing cardiology. Dr. Jeffrey Popma, MD, has directed numerous clinical trials for these new devices. This ongoing research is critical for bringing new treatment options to patients with limited alternatives.
Clinical Trials and Medical Innovation
Dr. Popma has directed over 20 years of multi-center cardiovascular device clinical trials. His work has been instrumental in evaluating a broad array of new technologies. These include drug-eluting stents, distal protection devices, and carotid stenting systems.
This rigorous clinical research is essential for proving the safety and efficacy of new medical devices. Dr. Popma's leadership in this area ensures that new treatments are thoroughly vetted before becoming widely available to patients. His contributions have directly shaped modern interventional cardiology practice.
Expert Career and Research Highlights
Dr. Jeffrey Popma, MD, is a Professor of Medicine at Harvard Medical School. He serves as the Director of Interventional Cardiology at Beth Israel Deaconess Medical Center in Boston. His leadership roles also include past president of the Society for Cardiovascular Angiography & Interventions (SCAI).
Dr. Popma has an immense publication record with over 500 peer-reviewed articles. He has also authored numerous textbook chapters on interventional cardiology techniques. His current role as a Chief Medical Officer allows him to guide the development of the next generation of life-saving cardiac devices.
Full Transcript
Dr. Anton Titov, MD: Hello from Boston! I am Dr. Anton Titov, MD. We are with Dr. Jeffrey Popma. He is Professor of Medicine at Harvard Medical School and Director of the Interventional Cardiology program at Beth Israel Deaconess Hospital in Boston.
In 2020, Dr. Jeffrey Popma became Vice President and Chief Medical Officer of the Coronary, Renal Denervation, and Structural Heart businesses at Medtronic. Dr. Popma obtained his MD from Indiana University School of Medicine.
He did his residency and fellowship at University of Texas Southwestern Medical Center and University of Michigan. Dr. Popma is an internationally renowned interventional cardiology expert and a transcatheter aortic valve replacement expert.
He is also an expert in transcatheter mitral and tricuspid valve therapies. Dr. Jeffrey Popma is past President of the Society of Cardiac Angiography and Interventions and served as Chairman of the American College of Cardiology Cardiac Catheterization Committee.
Dr. Popma has directed numerous multi-center cardiovascular device clinical trials. Over the past 20 years, these clinical trials have included a broad array of new technology, including aortic valve prostheses, bare metal stents, drug-eluting stents, distal protection devices, total occlusion devices, and carotid and peripheral revascularization procedures.
Dr. Popma has published over 500 scientific articles in international peer-reviewed medical journals and presented hundreds of talks at international cardiology meetings. He has also published many textbook chapters on interventional cardiology and transcatheter valve replacement topics.
Dr. Popma, hello and welcome!
Dr. Jeffrey Popma, MD: Hello! Thank you! It is very humbling to be here, thank you so much!
Dr. Anton Titov, MD: Transcatheter aortic valve replacement, TAVR, or transcatheter aortic valve implantation, TAVI. How do we compare minimally invasive methods of aortic valve replacement with open heart surgical operation to replace the aortic valve?